ArticleBMC pharmacology & toxicology2026
Lipid-coated mesoporous silica nanoparticles loaded with Thymoquinone as a novel treatment for experimental autoimmune encephalomyelitis in rats.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCrossing the blood-brain barrier (BBB) remains a significant challenge for delivering therapeutic agents to the central nervous system. This study aimed to evaluate the potential of a novel nanoformulation-mesoporous silica nanoparticles (MSN) coated with a lipid bilayer (LB)-to enhance the delivery and potential remyelinating effects of Thymoquinone (TQ).
methodsThe formulations were characterized by transmission electron microscopy and dynamic light scattering for zeta potential and particle size determination. The experimental autoimmune encephalomyelitis (EAE) model is used as an established animal model for multiple sclerosis (MS). Our experiment consists of five groups of male Wistar rats: a standard control group, an EAE-induced group, and three treated groups after being induced with EAE: (Thymoquinone) TQ-treated group (60 mg/kg TQ), MSN-treated group (60 mg/kg MSN), and LB-MSN-treated group (60 mg/kg MSN loaded with TQ and coated with lipid bilayer). KEY
findingsThe LB-MSN formulation was associated with a modulation of oxidative stress markers in specific brain areas. Notable increases in reduced glutathione were observed in the cortex (26.53%) and hippocampus (22.82%), alongside a modest increase in catalase in the medulla (7.90%). These biochemical changes correlated with improvements in exploratory behavior in the open field test. Furthermore, neuropathological assessment of various brain regions and sciatic nerves revealed evidence of axonal remyelination in treated groups. SIGNIFICANCE: The findings suggest that the LB-MSN formulation may enhance the delivery and therapeutic profile of TQ, primarily through its association with anti-inflammatory and remyelinating effects.
conclusionLB-MSN shows potential as a drug delivery system for the management of EAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.